GuruFocus Manual of Stocks™  |  Jan 23, 2022
Cellectar Biosciences Inc (NAS:CLRB)
www.gurufocus.com/stock/NAS:CLRB
Cellectar Biosciences Inc (NAS:CLRB)
[1]
[5]$ 0.54
Biotechnology
Market Cap: $ 33 Mil
Cellectar Biosciences Inc is a biopharmaceutical company. It is engaged in developing compounds for treatment and imaging of cancer. Its portfolio consists of PET imaging agents, optical imaging agents, and therapeutic agents.
Valuation Rank
Score: 0 /10CurrentIndustry MedianHistorical Median
PE RatioLoss30.840.06
Forward P/EN/A19.06N/A
PB Ratio0.892.810.32
PS RatioN/A15.090.84
P/FCFN/A33.80N/A
Shiller P/EN/A47.41N/A
PEG RatioN/A2.00N/A
Valuation Analysis
% of Price
Price0.54
NCAV0.6111
Tangible Book0.61113
Dividend & Ownership
Dividend Yield(ttm) %N/A
Dividend Yield(forward) %N/A
PayoutN/A
Dividend Growth(5y) %N/A
Yield on Cost(5y) %N/A
Continuous Div. sinceN/A
Insider Ownership %1.17
Institution Ownership %6.79
Financial Strength
Score: 7 /10CurrentIndustry MedianHistorical Median
Cash-to-Debt121.1613.94125.31
Equity-to-Asset0.920.760.77
Interest CoverageN/A228.18No Debt
Piotroski F-Score233
Profitability Rank
Score: 1 /10CurrentIndustry MedianHistorical Median
Operating Margin %0.00-202.810.00
Net Margin %0.00-204.830.00
ROE %-53.65-38.74-127.61
ROA %-48.68-31.09-87.32
ROC (Joel Greenblatt) %-3786.82-475.41-525.30
Growth (Per Share)
10 Yr5 Yr1 Yr
Revenue Growth (%)N/AN/AN/A
EBITDA Growth (%)51.660.7N/A
Oprt. Income Growth (%)51.861.1N/A
EPS w/o NRI Growth (%)51.858.4N/A
Free Cash Flow Growth (%)51.561.4N/A
Book Value Growth (%)-48-51.28.4
Quarterly
Sep20Dec20Mar21Jun21Sep21
Revenue----------
Net Income-4-4-6-6-6
EPS-0.15-0.07-0.13-0.11-0.1
Revenue (YoY) %----------
Net Income (YoY) %0.156.9560.6166.8948.82
EPS (YoY) %-64.29-78.79-69.05-57.69-33.33
Warning Signs
SEVEREPiotroski F-Score: Low
Good Signs
GOODBeneish M-Score: Unlikely manipulator
GOODInterest Coverage: Comfortable
GOODPrice: Close to 10-year low
Insider Trades
InsiderPositionDateTradesCur. Shares
Swirsky Douglas JDirector09/14/212500025000
Driscoll Frederick WDirector09/03/211941719417
Caruso James VPresident and C03/04/21510086401
As of 01-23-2022
* All financial numbers are in millions except for per share data, ratios and percentage change.
Gain % SP500 %
1W-22.74-5.75
1M-18.85-5.42
3M-41.31-3.10
6M-52.211.47
YTD-18.67-7.79
1Y-72.1615.50
3Y-35.5819.94
5Y-46.9116.09
10Y-52.3814.91
4000
1999.73
0.54
4M
2.2M
2012201320142015201620172018201920202021CurrentPerformance
153004000158084035576.1526.613.72.853.172.98Highest Stock Price
740860600198.9568.510.511.21.291.061.030.53Lowest Stock Price
16342123613237219533Market Cap
00000.10.41.437.719.859.9Shares Outstanding-Diluted
At LossAt LossAt LossAt LossAt LossAt LossAt LossAt LossAt LossAt LossAt LossPE Ratio
1.713.3812.493.493.8212.340.682.672.720.89PB Ratio
----------------------PS Ratio
-1.68-3.65-1.77-1.55-0.34-0.24-1.150.29-0.87-3.820.26EV-to-EBITDA
2011201220132014201520162017201820192020TTMPer Share Data
----------------------Revenue per Share
-620-460-386-175.3-70.3-21.4-10.7-5.23-1.84-0.76-0.41Earnings per Share
-507.33-318.24-332.25-192.83-106.04-19.12-8.1-3.99-1.53-0.71-0.47Free Cash Flow per Share
----------------------Dividends per Share
423.09365.650.8766.42-0.2910.614.852.270.840.770.61Tangible Book per Share
----------------------Median PS Value
----------------------Graham Number
2011201220132014201520162017201820192020TTMIncome Statement
----------------------Revenue
----------------------Gross Profit
----------------------Gross Margin %
6.38.811.39.78.69.513.611.714.215.322Total Operating Expense
-6.3-8.8-11.3-9.7-8.6-9.5-13.6-11.7-14.2-15.3-22Operating Income
----------------------Operating Margin %
-7.4-8.8-10.8-8.1-5.5-6.2-13.6-13.2-14.1-15.1-21.8Net Income
----------------------Net Margin %
-7.3-8.8-11.3-9.7-8.6-9.5-13.6-11.7-14.2-15.3-22EBIT
-6.7-8.3-10.9-9.3-8.2-9.1-12.1-11.6-14-15.1-21.9EBITDA
-154.7-95.1-181.9-191.8-131.7-123.2-123.6-128.9-126.3-47.3-53.7ROE %
-96.8-79.8-117.9-79.6-52.3-53.9-96.2-94.8-103.2-42.6-48.7ROA %
2011201220132014201520162017201820192020Sep21Balance Sheet
5.54.72.49.43.911.41013.310.657.240.3Cash & Equivalents
----------------------Total Receivables
10.611.56.813.47.615.312.915.112.358.742Total Assets
0000.10.20.1000.10.10.1Short-Term Debt & CLO
0.50.50.50.30.100--0.40.30.2Long-Term Debt & CLO
1.11.35.16.75.91.82.11.83.23.93.4Total Liabilities
9.510.21.76.71.713.510.813.39.154.838.6Total Stockholders Equity
9.510.21.76.71.713.510.813.39.154.838.6Total Equity
2011201220132014201520162017201820192020TTMCashflow Statement
-6-6.6-9.2-8.8-8.2-8.3-11-11.4-11.7-13.9-21.9Cash Flow from Operations
1.3-2.11.9-0-0.1-0.1-0.3-0.3-0-0.1-0Cash Flow from Investing
----------------------Repurchase of Stock
-0.7-0-04-0.1-0.2-0.1-0-00.2--Net Issuance of Debt
9.57.9515.92.715.99.915960.543.5Cash Flow from Financing
4.8-0.8-2.37-5.67.6-1.43.2-2.746.621.5Net Change in Cash
-0.1-0.1-0.1-0-0.1-0.1-0.3-0.4-0-0.1-0Capital Expenditure
-6.1-6.7-9.3-8.9-8.3-8.4-11.4-11.8-11.7-14-21.9Free Cash Flow
Competitor
TickerCompanyFinancial
Strength
Profitability
Rank
Market Cap
($M)
PE RatioPS RatioNet
Margin %
ROA %ROE %
OTCPK:INTIInhibitor Therapeutics Inc3153N/A0.000.00-265.730.00
NAS:TCONTRACON Pharmaceuticals Inc3141At Loss96.82-7302.31-80.59-137.77
NAS:CLRBCellectar Biosciences Inc7133At Loss0.000.00-48.68-53.65
NAS:BBIBrickell Biotech Inc4127At Loss46.60-12468.50-133.99-173.78
NAS:TENXTenax Therapeutics Inc6016At Loss0.000.00-497.98-673.23
GuruFocus Manual of Stocks™  |  Jan 23, 2022
Cellectar Biosciences Inc (NAS:CLRB)
www.gurufocus.com/stock/NAS:CLRB

Financial Strength[2] (Quarterly data, as of Sep. 2021) : Good (7/10)

0
1
2
3
4
5
6
7
8
9

Cash-to-Debt : 121.16

Cash-to-Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. A high ratio indicates that a company is better able to pay back its debt, and is thus able to take on more debt if necessary.


Equity-to-Asset : 0.92

Equity-to-Asset ratio is calculated as total stockholders equity divided by its total assets. Equity-to-Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity-to-Asset ratio (more leveraged) may have higher ROE % because of the leverage.


Debt-to-Equity : 0.01

A high Debt-to-Equity ratio generally means that a company has been aggressive in financing its growth with debt.


Piotroski F-Score : 2

The Piotroski F-Score is used to determine the strength of a firm's financial position, with 9 being the best and 0 being the worst.

0
1
2
3
4
5
6
7
8
9


WACC : 11.50% vs ROIC : -2237.14%

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business.


Dividend Yield : 0.00%

Dividend yield is a way to measure how much cash flow you are getting for each dollar invested in an equity position.

GuruFocus Manual of Stocks™  |  Jan 23, 2022
Cellectar Biosciences Inc (NAS:CLRB)
www.gurufocus.com/stock/NAS:CLRB

Profitability[3] (Annual data, as of Dec. 2020) : Poor (1/10)

0
1
2
3
4
5
6
7
8
9

Revenue : $0 Mil vs Net Income : $-6 Mil

Revenue is the amount of money that a company actually receives during a specific period, including discounts and deductions for returned merchandise. Net Income is a company's total profit. Net income is calculated by taking revenues and adjusting for the cost of doing business, depreciation, interest, taxes and other expenses.


Cash & Equivalents : $40 Mil vs Long-Term Debt* : $0 Mil

Cash & equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash. Long-Term Debt* consists of loans and obligations lasting over one year.


Operating Margin % : 0.00%

Operating margin % measures how much profit a company makes on a dollar of sales. Operating Margin % is calculated as Operating Income divided by Revenue.


EPS without NRI : $-0.10

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock. In calculating earnings per share without non-recurring items, the dividends of preferred stocks and Non Operating Income need to subtracted from the total net income first.


Dividends per Share : $0.00

Dividends per Share is the amount of dividends that the shareholders of a company receive on a per-share basis. It is calculated using the total dividends paid out to shareholders over one fiscal year and the number of shares outstanding.


Free Cash Flow per Share : $-0.11

Free Cash flow per Share is the amount of Free cash flow per outstanding share of the company's stock.

GuruFocus Manual of Stocks™  |  Jan 23, 2022
Cellectar Biosciences Inc (NAS:CLRB)
www.gurufocus.com/stock/NAS:CLRB

Valuation (Quarterly data, as of Sep. 2021)

These valuation metrics should give you a sense of reasonable prices, but be careful with them. Always seek to understand why a valuation is changing over time.


Valuation Chart (Current stock price : $0.54)


PE Ratio without NRI : At Loss

The price-to-earnings ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.


PB Ratio : 1.52

The price-to-book ratio measures the valuation of the stock relative to the underlying asset of the company.


PS Ratio : 0.00

The price-to-sales ratio is a valuation ratio that compares a company’s stock price to its revenues. The price-to-sales ratio is an indicator of the value placed on each dollar of a company’s sales or revenues.


Price-to-Free-Cash-Flow : 0.00

Price-to-free-cash-flow is very similar to the valuation metric of price-to-operating-cash-flow but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures from a company's total operating cash flow, thereby reflecting the actual cash flow available to fund non-asset-related growth.


EV-to-EBIT : -0.81

Enterprise value of a company divided by its trailing 12 months earnings before interest and taxes (EBIT).

GuruFocus Manual of Stocks™  |  Jan 23, 2022
Cellectar Biosciences Inc (NAS:CLRB)
www.gurufocus.com/stock/NAS:CLRB

Valuation Bands

In these charts the 10-year valuation bands of the price-to-earnings ratio (PE Ratio), price-to-book ratio (PB Ratio), price-to-sales ratio (PS Ratio) and price-to-operating-cash-flow ratio (POCF) are drawn together with the historical stock prices. For example, the upper line of the PE band is where the stock price would have been if it were always traded at the maximum PE ratio of the past 10 years. The lower line of the PE band is where the stock price would have been if it were always traded at the lowest PE ratio of the past 10 years. It is always better if the stock price is close to the lower line, which indicates a lower valuation.


Historical Price and PE Band


Historical Price and PS Band


Historical Price and PB Band


Historical Price and Price-to-Operating-Cash-Flow (POCF) Band

GuruFocus Manual of Stocks™  |  Jan 23, 2022
Cellectar Biosciences Inc (NAS:CLRB)
www.gurufocus.com/stock/NAS:CLRB

Warning Signs

GuruFocus conducted a thorough checkup using a checklist of 32 items that cover the areas of financial strength, profitability, growth, and valuation of each company. The purpose of Warning Signs is to warn you that the company may have red flags in certain areas, helping to avoid overlooking them. These warning signs do not necessarily mean you should not invest in the stock. But you should be aware of them before you invest.


Severe Warning Signs

Piotroski F-Score : Low

Piotroski F-Score of 2 is low, which usually implies poor business operation.

Good Signs

Beneish M-Score : Unlikely manipulator

Beneish M-Score -3.2 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

Interest Coverage : Comfortable

Ben Graham prefers companies interest coverage is at least 5. Cellectar Biosciences Inc has enough cash to cover all of its debt. Its financial situation is stable.

Price : Close to 10-year low

Cellectar Biosciences Inc stock Price is close to 10-year low
GuruFocus Manual of Stocks™  |  Jan 23, 2022
Cellectar Biosciences Inc (NAS:CLRB)
www.gurufocus.com/stock/NAS:CLRB

Competitive Comparison


5 Year Price Change Comparison


Financial Strength

CompanyFinancial StrengthCash-to-DebtEquity-to-AssetDebt-to-EquityInterest CoveragePiotroski F-ScoreAltman Z-ScoreBeneish M-ScoreWACC %ROIC %
NAS:CLRBCellectar Biosciences Inc7/10121.160.920.01N/A20.00-3.2011.50-2237.14
NAS:ACHVAchieve Life Sciences Inc6/10362.090.920.00N/A30.00-0.197.13-707.44
NAS:TENXTenax Therapeutics Inc6/1026.440.810.040.0010.00-15.6513.41-4883.76
NAS:BBIBrickell Biotech Inc4/10292.920.830.000.003-8.810.008.70-2966.42
OTCPK:INTIInhibitor Therapeutics Inc3/100.23-38.03-0.070.0010.00-6.44-6.20-239.48

Profitability

CompanyProfitability RankOperating
Margin %
Net Margin %ROE %ROA %Price-to-Free-Cash-FlowROC (Joel Greenblatt) %3-Year Revenue Growth %3-Year EBITDA Growth %3-Year EPS w/o NRI Growth %
NAS:ACHVAchieve Life Sciences Inc1/100.000.00-91.12-83.070.00-19356.870.0072.8076.90
NAS:BBIBrickell Biotech Inc1/10-12642.20-12468.50-173.78-133.990.00-35520.94-78.6050.0050.60
NAS:CLRBCellectar Biosciences Inc1/100.000.00-53.65-48.680.00-3786.820.0055.3058.60
OTCPK:INTIInhibitor Therapeutics Inc1/100.000.000.00-265.730.000.000.0040.2033.10
NAS:TENXTenax Therapeutics Inc0/100.000.00-673.23-497.980.00-18745.910.0047.6046.70

Valuation

CompanyPE RatioPB RatioPS RatioPrice-to-Intrinsic-Value-Projected-FCFPrice-to-Intrinsic-Value-DCF (Earnings Based)Price-to-Median-PS-ValuePrice-to-Peter-Lynch-Fair-ValuePrice-to-Graham-NumberEarnings Yield (Joel Greenblatt) %Forward Rate of Return (Yacktman) %
NAS:ACHVAchieve Life Sciences IncAt Loss2.130.000.000.000.000.000.00-75.190.00
NAS:BBIBrickell Biotech IncAt Loss1.0446.600.000.0011.650.000.00-714.290.00
NAS:CLRBCellectar Biosciences IncAt Loss0.890.000.000.000.000.000.00384.620.00
NAS:TENXTenax Therapeutics IncAt Loss2.250.000.000.000.000.000.00-384.620.00
OTCPK:INTIInhibitor Therapeutics IncN/A0.000.000.000.000.000.000.00-0.550.00
GuruFocus Manual of Stocks™  |  Jan 23, 2022
Cellectar Biosciences Inc (NAS:CLRB)
www.gurufocus.com/stock/NAS:CLRB

Peter Lynch Chart[4]

GuruFocus Manual of Stocks™  |  Jan 23, 2022
Cellectar Biosciences Inc (NAS:CLRB)
www.gurufocus.com/stock/NAS:CLRB

Per Share Data



Per Share Data

Dec05
Dec06
Dec07
Dec08
Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
TTM Fiscal Period
--
--
--
969
686
--
--
--
--
--
--
--
--
--
--
--
-- Revenue per Share
--
-68615
-155992
-127492
-72386
-594
-556
-393
-389
-202
-105
-20.81
-8.59
-3.91
-1.83
-0.77
-0.47
EBITDA per Share
--
-68692
-156108
-127623
-72614
-690
-605
-417
-404
-210
-110
-21.63
-9.69
-3.94
-1.85
-0.77
-0.47
EBIT per Share
-23855
-66775
-232198
-160565
-115787
-720
-620
-460
-386
-175
-70.3
-21.4
-10.7
-5.23
-1.84
-0.76
-0.41
Earnings per Share (Diluted)
-428
-7038
-10000
-10000
-10000
-720
-620
-460
-386
-175
-70.3
-21.4
-10.7
-5.23
-1.84
-0.76
-0.41
EPS without NRI
--
--
--
--
-131259
521
-479
-356
-345
-105
-63.87
-5.44
-6.95
-2.93
-1.35
-0.49
-0.38
Owner Earnings per Share (TTM)
--
-49846
-103785
-133700
-75971
-564
-507
-318
-332
-193
-106
-19.12
-8.1
-3.99
-1.53
-0.71
-0.47
Free Cash Flow per Share
--
-49762
-103600
-133323
-75843
-564
-498
-314
-327
-192
-105
-18.95
-7.86
-3.86
-1.52
-0.7
-0.47
Operating Cash Flow per Share
32823
76446
74938
9014
38130
455
298
202
84.25
125
44.96
11.04
6.01
2.8
1.13
1.26
0.66
Cash per Share
36323
81615
-45154
-139207
-116939
90.54
514
438
59.23
88.56
19.23
12.23
5.86
2.27
0.84
0.77
0.61
Book Value per Share
36323
81615
-45154
-139207
-116939
90.54
423
366
0.87
66.42
-0.29
10.61
4.85
2.27
0.84
0.77
0.61
Tangible Book per Share
--
--
--
--
--
2605
24.72
19.57
15.75
6.12
3.97
0.09
0
--
0.06
0.01
0.01
Total Debt per Share
611995
266218
180539
143819
770808
7925
880
1480
740
309
73.5
12.2
13.7
1.55
2.25
2.08
0.54
Month End Stock Price

Ratios

Dec05
Dec06
Dec07
Dec08
Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
TTM Fiscal Period
-64.65
-111
-1254
--
--
--
-155
-95.12
-182
-192
-132
-123
-124
-129
-126
-47.28
-53.65
ROE %
-3.84
-34.2
--
--
--
--
-90.44
-28.14
-14.56
-54.95
-34.46
-123
-52.81
-190
-47.3
-17.38
-60.28
ROE % Adjusted to Book Value
-61.81
-98.28
-170
-262
-428
-66.4
-96.78
-79.82
-118
-79.58
-52.29
-53.92
-96.2
-94.82
-103
-42.57
-48.68
ROA %
-64.65
-111
-1254
--
--
--
-187
-115
-253
-319
-220
-158
-143
-139
-126
-47.28
-53.65
Return-on-Tangible-Equity
-61.81
-98.28
-170
-262
-428
-66.4
-109
-94.13
-144
-95.37
-62.21
-63.15
-109
-101
-103
-42.57
-48.68
Return-on-Tangible-Asset
-752
-1781
-5840
-36464
-19933
-233
-221
-308
-452
-440
-455
-596
-1611
-2958
-2137
-2150
-3787
ROC (Joel Greenblatt) %
-54.34
-116
-277
--
--
--
-104
-84.17
-173
-204
-188
-121
-111
-96.37
-124
-47.35
-53.71
ROCE %
-564
-1585
-5637
-21408
-190
-57.88
-148
-157
-164
-118
-97.97
-160
-429
-510
-960
-1001
-2237
ROIC %
--
10.69
10.04
10.61
13.59
10.09
4.27
-0.3
3.12
1.01
5.96
7.08
12.03
7.59
10.7
10.83
11.5
WACC %
--
--
--
--
--
14.68
8.21
1.98
1.99
97.49
0.25
--
--
--
--
--
-- Effective Interest Rate on Debt %
-19738
--
--
-13167
-10590
--
--
--
--
--
--
--
--
--
--
--
-- Operating Margin %
-23485
--
--
-13056
-23201
--
--
--
--
--
--
--
--
--
--
--
-- Net Margin %
-18654
--
--
-13794
-11079
--
--
--
--
--
--
--
--
--
--
--
-- FCF Margin %
--
--
--
--
--
28.77
0.05
0.05
0.27
0.07
0.21
0.01
--
--
0.06
0.01
0.01
Debt-to-Equity
0.96
0.89
-0.53
-13.29
-3.01
0.03
0.9
0.89
0.25
0.5
0.22
0.88
0.84
0.88
0.74
0.93
0.92
Equity-to-Asset
--
--
--
--
--
0.8
0.04
0.04
0.07
0.04
0.05
0.01
--
--
0.04
0.01
0.01
Debt-to-Asset
0.04
0.11
1.53
14.29
4.01
0.97
0.1
0.12
0.75
0.5
0.78
0.12
0.16
0.12
0.26
0.07
0.08
Liabilities-to-Assets
0.26
--
--
2
1.85
--
--
--
--
--
--
--
--
--
--
--
-- Gross-Profit-to-Asset %
0
--
--
0.02
0.02
--
--
--
--
--
--
--
--
--
--
--
-- Asset Turnover
2
--
--
0.39
0.19
--
--
--
--
--
--
--
--
--
--
--
-- Capex-to-Revenue
* All financial numbers are in millions except for per share data, ratios and percentage change. When Return-on-Tangible-Equity displays Neg. E, it means the the tangible equity is negative.
GuruFocus Manual of Stocks™  |  Jan 23, 2022
Cellectar Biosciences Inc (NAS:CLRB)
www.gurufocus.com/stock/NAS:CLRB

Financial Satement



Income Statement

Dec05
Dec06
Dec07
Dec08
Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
TTM Fiscal Period
0.01
--
--
0.13
0.1
--
--
--
--
--
--
--
--
--
--
--
-- Revenue
0.01
--
--
0.13
0.1
--
--
--
--
--
--
--
--
--
--
--
-- Gross Profit
1.44
2.49
2.87
2.19
2.18
1.16
2.69
3.63
4.45
3.71
3.4
4.7
4.14
4.82
5.18
5.15
6.43
Selling, General, & Admin. Expense
1.14
6.44
17.43
14.53
8.08
2.98
3.6
5.12
6.86
5.96
5.16
4.75
9.47
6.84
9
10.14
15.57
Research & Development
-0
0
-0
0
0
--
0
0
-0
--
0
0
0
-0
--
-0
0
Other Operating Expense
2.58
8.93
20.29
16.72
10.26
4.14
6.29
8.76
11.31
9.67
8.55
9.45
13.6
11.66
14.18
15.29
22.01
Total Operating Expense
-2.57
-8.93
-20.29
-16.59
-10.17
-4.14
-6.29
-8.76
-11.31
-9.67
-8.55
-9.45
-13.6
-11.66
-14.18
-15.29
-22.01
Operating Income
-19738
--
--
-13167
-10590
--
--
--
--
--
--
--
--
--
--
--
-- Operating Margin %
--
--
--
0.13
0
0
0.01
0
--
--
--
--
--
--
0.04
0.01
0
  Interest Income
--
--
--
--
--
-0.57
-0.18
-0.01
-0.01
-0.45
-0
--
--
--
--
--
--   Interest Expense
--
--
--
0.13
0
-0.57
-0.43
-0.01
-0.01
-0.45
-0
0.01
0.02
0.03
0.04
0.01
0
Net Interest Income
2.57
8.93
20.29
16.46
10.17
4.71
-0.71
-0.03
0.53
2.06
3.06
3.26
0.02
-1.61
0.04
0.19
0.19
Other Income (Expense)
--
--
--
--
--
--
-7.44
-8.8
-10.78
-8.05
-5.5
-6.18
-13.56
-13.24
-14.09
-15.09
-21.82
Pre-Tax Income
-3.05
-8.29
-19.56
-16.45
-22.27
-4.56
-7.44
-8.8
-10.78
-8.05
-5.5
-6.18
-13.56
-13.24
-14.09
-15.09
-21.82
Net Income (Continuing Operations)
-3.05
-8.29
-19.56
-16.45
-22.27
-4.56
-7.44
-8.8
-10.78
-8.05
-5.5
-6.18
-13.56
-13.24
-14.09
-15.09
-21.82
Net Income
-23485
--
--
-13056
-23201
--
--
--
--
--
--
--
--
--
--
--
-- Net Margin %
--
0.26
10.16
6.51
4.01
14.75
--
0.54
--
--
--
3.18
1.45
2.24
--
--
-- Preferred Dividends
-23855
-66775
-232198
-160565
-115787
-720
-620
-460
-386
-175
-70.3
-21.4
-10.7
-5.23
-1.84
-0.76
-0.41
EPS (Basic)
-23855
-66775
-232198
-160565
-115787
-720
-620
-460
-386
-175
-70.3
-21.4
-10.7
-5.23
-1.84
-0.76
-0.41
EPS (Diluted)
--
0
0
0
0
0.01
0.01
0.02
0.03
0.05
0.08
0.44
1.4
2.96
7.68
19.81
59.87
Shares Outstanding (Diluted Average)
-2.57
-8.93
-20.29
-16.59
-10.17
-4.14
-7.26
-8.76
-11.31
-9.67
-8.55
-9.45
-13.6
-11.66
-14.18
-15.29
-22.01
EBIT
0
0.01
0.02
0.02
0.03
0.58
0.59
0.5
0.43
0.37
0.36
0.36
1.55
0.08
0.13
0.14
0.15
Depreciation, Depletion and Amortization
-2.56
-8.92
-20.28
-16.57
-10.13
-3.56
-6.67
-8.26
-10.88
-9.3
-8.19
-9.09
-12.06
-11.57
-14.05
-15.15
-21.86
EBITDA

Cashflow Statement

Dec05
Dec06
Dec07
Dec08
Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
TTM Fiscal Period
-3.05
-8.29
-19.56
-16.45
-22.27
2.1
-7.44
-8.8
-10.78
-8.05
-5.5
-6.18
-13.56
-13.24
-14.09
-15.09
-21.82
Net Income From Continuing Operations
0
0.01
0.02
0.02
0.03
0.58
0.59
0.5
0.43
0.37
0.36
0.36
1.55
0.08
0.13
0.14
0.15
Depreciation, Depletion and Amortization
0.01
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--   Change In Receivables
-0.1
0.12
0.16
0
0.03
0.02
-0.18
-0.07
0.05
0.07
-0.01
-0.46
0.28
-0.23
-0.13
-0
-0.09
  Change In Prepaid Assets
-0.14
0.87
5.28
-1.83
-1.35
-0.02
-0.14
0.24
0.45
-0.23
-0.26
0.74
0.45
-0.26
1.12
0.78
-0.8
  Change In Payables And Accrued Expense
0.04
0.23
0.12
0.47
-0.03
0.01
0.01
0.01
0.01
0.01
0
-0
-0.47
-0.08
0.4
-0.11
-0.12
  Change In Other Working Capital
-0.18
1.22
5.57
-1.36
-1.36
0.01
-0.3
0.18
0.5
-0.15
-0.27
0.27
0.26
-0.57
1.39
0.67
-1.01
Change In Working Capital
--
--
--
0.45
0.86
0.35
0.91
1.5
2.32
0.85
0.45
0.53
0.76
0.72
0.87
0.47
0.85
Stock Based Compensation
--
--
--
--
--
0.02
--
--
--
--
--
--
--
1.68
--
--
-- Asset Impairment Charge
0.83
0.59
0.5
0.01
12.12
-6.44
0.27
0.04
-1.62
-1.86
-3.27
-3.26
-0.02
-0.11
0.01
-0.12
-0.1
Cash Flow from Others
-2.4
-6.47
-13.47
-17.33
-10.62
-3.38
-5.97
-6.59
-9.16
-8.84
-8.21
-8.28
-11.02
-11.44
-11.69
-13.93
-21.93
Cash Flow from Operations
-0.03
-0.01
-0.02
-0.05
-0.02
-0
-0.12
-0.1
-0.15
-0.03
-0.06
-0.07
-0.35
-0.39
-0.03
-0.06
-0.03
Purchase Of Property, Plant, Equipment
--
--
--
--
--
--
--
--
--
--
--
--
--
0.06
--
--
-- Sale Of Property, Plant, Equipment
--
--
--
--
--
--
0.91
--
--
--
--
--
--
--
--
--
-- Sale Of Business
-0.23
-1.44
0.47
1.19
--
--
0.5
-2
2
--
--
--
--
-0
--
--
-- Cash From Other Investing Activities
-0.25
-1.45
0.44
1.14
-0.02
-0
1.29
-2.1
1.85
-0.03
-0.06
-0.07
-0.35
-0.33
-0.03
-0.06
-0.03
Cash Flow from Investing
6.58
13.85
13.69
2.99
8.94
--
10.17
6.84
4.98
12.4
3.3
12.36
4.91
9.08
9.03
59.72
-- Issuance of Stock
--
--
-0.04
--
--
1.25
--
--
--
--
--
--
--
--
--
--
-- Repurchase of Stock
--
--
--
5.47
9.21
--
--
--
--
--
--
3.46
2.27
5.95
--
--
-- Net Issuance of Preferred Stock
0.33
--
--
--
--
3.17
--
--
--
4.62
--
--
--
--
--
0.18
--   Issuance of Debt
--
--
--
--
--
-0.19
-0.68
-0
-0
-0.62
-0.12
-0.25
-0.09
-0
-0
--
--   Payments of Debt
0.33
--
--
--
--
2.98
-0.68
-0
-0
4
-0.12
-0.25
-0.09
-0
-0
0.18
-- Net Issuance of Debt
--
--
-0.82
-0.74
--
--
--
--
--
--
--
--
--
--
--
--
-- Cash Flow for Dividends
--
-0.26
0
--
-0
-1.15
0.03
1.02
0.07
-0.52
-0.47
0.36
2.85
-0
-0
0.64
-- Other Financing
6.91
13.59
12.83
7.72
18.14
3.08
9.52
7.85
5.04
15.87
2.71
15.94
9.93
15.02
9.02
60.55
43.46
Cash Flow from Financing
4.26
5.67
-0.2
-8.48
7.51
-0.31
4.83
-0.83
-2.26
7
-5.56
7.59
-1.44
3.25
-2.7
46.55
21.5
Net Change in Cash
-0.03
-0.01
-0.02
-0.05
-0.02
-0
-0.12
-0.1
-0.15
-0.03
-0.06
-0.07
-0.35
-0.39
-0.03
-0.06
-0.02
Capital Expenditure
-2.43
-6.48
-13.49
-17.38
-10.64
-3.38
-6.09
-6.68
-9.3
-8.87
-8.27
-8.35
-11.37
-11.83
-11.72
-14
-21.94
Free Cash Flow
* All financial numbers are in millions except for per share data, ratios and percentage change.
GuruFocus Manual of Stocks™  |  Jan 23, 2022
Cellectar Biosciences Inc (NAS:CLRB)
www.gurufocus.com/stock/NAS:CLRB

Financial Satement


Balance Sheet

Dec05
Dec06
Dec07
Dec08
Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
TTM Fiscal Period
4.27
9.94
9.74
1.26
8.77
0.67
5.51
4.68
2.42
9.42
3.86
11.45
10.01
13.26
10.62
57.17
40.35
  Cash And Cash Equivalents
4.27
9.94
9.74
1.26
8.77
0.67
5.51
4.68
2.42
9.42
3.86
11.45
10.01
13.26
10.62
57.17
40.35
Cash, Cash Equivalents, Marketable Securities
0.53
1.95
1.32
0.13
0.1
0.61
0.31
0.45
0.35
0.28
0.32
0.75
0.47
0.7
0.77
0.77
1.05
Other Current Assets
4.8
11.89
11.06
1.39
8.87
1.28
5.82
5.13
2.77
9.7
4.18
12.19
10.47
13.95
11.39
57.94
41.39
Total Current Assets
--
--
--
0.02
0.02
--
--
--
--
--
--
--
--
--
--
--
-- Investments And Advances
0
--
0
--
--
--
--
--
--
--
--
--
--
--
0.35
0.28
0.23
  Buildings And Improvements
0.05
--
0.05
0.1
0.12
2.98
3.07
3.16
3.3
3.32
3.35
3.36
3.76
0.42
0.44
0.45
--   Machinery, Furniture, Equipment
--
--
--
--
--
--
--
--
--
--
--
0.06
--
--
--
--
--   Construction In Progress
-0
0.06
0.01
0
0
2.32
2.33
2.34
2.32
2.33
2.33
2.33
2.33
0.31
0.31
0.31
0.25
  Other Gross PPE
0.05
0.06
0.06
0.1
0.12
5.3
5.4
5.49
5.63
5.65
5.67
5.75
6.09
0.73
1.09
1.04
0.48
Gross Property, Plant and Equipment
-0.03
-0.04
-0.03
-0.05
-0.08
-1.79
-2.35
-2.85
-3.27
-3.61
-3.95
-4.3
-5.84
-0.18
-0.31
-0.4
--   Accumulated Depreciation
0.02
0.02
0.03
0.06
0.04
3.51
3.05
2.65
2.36
2.03
1.73
1.44
0.25
0.54
0.78
0.64
0.48
Property, Plant and Equipment
--
--
--
--
--
--
1.68
1.68
1.68
1.68
1.68
1.68
1.68
--
--
--
-- Intangible Assets
--
--
--
--
--
--
1.68
1.68
1.68
1.68
1.68
1.68
1.68
--
--
--
--   Goodwill
0.11
0.01
0.02
0
0
0.01
0.03
2.03
0.01
0.01
0.01
0.01
0.48
0.56
0.08
0.08
0.08
Other Long Term Assets
0.14
0.03
0.05
0.07
0.06
3.52
4.75
6.35
4.05
3.72
3.42
3.13
2.4
1.1
0.87
0.72
0.56
Total Long-Term Assets
4.94
11.92
11.11
1.47
8.93
4.8
10.56
11.48
6.82
13.42
7.6
15.33
12.87
15.05
12.25
58.66
41.95
Total Assets
0.21
1.09
6.37
4.65
3.3
0.39
0.48
--
--
--
--
--
0.93
0.61
1.28
1.43
--   Accounts Payable
--
--
--
1.69
2.9
--
--
--
--
--
--
--
--
--
--
--
--   Other Current Payables
0.01
0.23
0.69
0.24
0.25
0.31
--
0.72
1.16
0.93
0.68
1.42
0.59
0.52
0.99
1.16
3.03
  Current Accrued Expense
0.22
1.31
7.06
6.58
6.45
0.7
0.48
0.72
1.16
0.93
0.68
1.42
1.53
1.14
2.27
2.59
3.03
Accounts Payable & Accrued Expense
--
--
--
--
--
0.21
--
--
--
0.12
0.24
0.09
--
--
--
--
--   Short-Term Debt
--
--
--
--
--
0
0
0
0
0
0
0
0
0
0.11
0.12
0.13
  Short-Term Capital Lease Obligation
--
--
--
--
--
0.21
0
0
0
0.12
0.25
0.09
0
0
0.11
0.12
0.13
Short-Term Debt & Capital Lease Obligation
--
--
--
0.03
0.03
--
--
--
--
--
--
--
--
--
--
--
--   Current Deferred Revenue
--
--
--
0.03
0.03
--
--
--
--
--
--
--
0.14
0.03
--
--
-- DeferredTaxAndRevenue
--
--
--
--
10.49
0
0.02
0.01
3.36
5.18
4.78
0.13
0.45
0.45
0.4
0.85
0
Other Current Liabilities
0.22
1.31
7.06
6.62
16.97
0.91
0.5
0.73
4.52
6.23
5.7
1.63
2.12
1.62
2.77
3.56
3.17
Total Current Liabilities
--
--
--
--
--
3.64
0.45
0.45
0.45
0.33
0.09
--
--
--
--
--
--   Long-Term Debt
--
--
--
--
--
0.01
0
0
--
0.01
0.01
0.01
0
--
0.42
0.3
0.2
  Long-Term Capital Lease Obligation
--
--
--
--
--
3.65
0.45
0.45
0.45
0.34
0.1
0.01
0
--
0.42
0.3
0.2
Long-Term Debt & Capital Lease Obligation
--
--
--
--
--
28.77
0.05
0.05
0.27
0.07
0.21
0.01
--
--
0.06
0.01
0.01
Debt-to-Equity
--
--
--
0.43
0.4
0.12
0.12
0.14
0.14
0.15
0.15
0.15
--
0.17
--
--
-- NonCurrent Deferred Liabilities
--
--
9.92
13.91
18.46
-0
0
0
-0
0
-0
-0
-0
-0
-0
0
-0
Other Long-Term Liabilities
--
--
9.92
14.34
18.86
3.76
0.58
0.59
0.59
0.49
0.24
0.15
0
0.17
0.42
0.3
0.2
Total Long-Term Liabilities
0.22
1.31
16.98
20.96
35.83
4.67
1.08
1.32
5.12
6.72
5.95
1.79
2.12
1.79
3.19
3.87
3.37
Total Liabilities
--
--
--
--
0
--
--
--
--
--
--
--
--
--
--
--
0
Common Stock
--
--
--
--
--
--
--
--
--
--
--
0.87
1
2.53
1.15
20.04
1.38
Preferred Stock
-15.4
-23.69
-43.24
-59.69
-76.07
-24.05
-31.48
-40.28
-51.06
-59.11
-64.61
-70.79
-84.35
-97.59
-112
-127
-145
Retained Earnings
20.12
34.29
37.37
40.2
49.18
24.18
40.96
50.44
52.76
65.81
66.26
83.46
94.11
108
120
162
182
Additional Paid-In Capital
0
0
0
-0
-0
0
0
-0
0
0
0
0
-0
0
0
0
-0
Other Stockholders Equity
4.72
10.61
-5.87
-19.49
-26.9
0.13
9.48
10.16
1.7
6.7
1.65
13.54
10.75
13.26
9.06
54.8
38.59
Total Stockholders Equity
4.72
10.61
-5.87
-19.49
-26.9
0.13
9.48
10.16
1.7
6.7
1.65
13.54
10.75
13.26
9.06
54.8
38.59
Total Equity
0.96
0.89
-0.53
-13.29
-3.01
0.03
0.9
0.89
0.25
0.5
0.22
0.88
0.84
0.88
0.74
0.93
0.92
Equity-to-Asset
* All financial numbers are in millions except for per share data, ratios and percentage change.
GuruFocus Manual of Stocks™  |  Jan 23, 2022
Cellectar Biosciences Inc (NAS:CLRB)
www.gurufocus.com/stock/NAS:CLRB

Valuation Ratios



Valuation Ratios

Dec05
Dec06
Dec07
Dec08
Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
TTM Fiscal Period
--
--
--
--
--
15.22
--
--
--
--
--
--
--
--
--
--
-- Price-to-Owner-Earnings
16.85
3.26
--
--
--
87.53
1.71
3.38
12.49
3.49
3.82
1
2.34
0.68
2.67
2.72
0.89
PB Ratio
16.85
3.26
--
--
--
87.53
2.08
4.05
850
4.65
--
1.15
2.82
0.68
2.67
2.72
0.89
Price-to-Tangible-Book
--
--
--
148
1124
--
--
--
--
--
--
--
--
--
--
--
-- PS Ratio
5792
--
--
150
1755
--
--
--
--
--
--
--
--
--
--
--
-- EV-to-Revenue
-29.38
-2.77
-0.68
-1.14
-16.63
-4.19
-1.68
-3.65
-1.77
-1.55
-0.34
-0.24
-1.15
0.29
-0.87
-3.82
0.26
EV-to-EBITDA
-29.34
-2.76
-0.68
-1.14
-16.58
-3.6
-1.54
-3.44
-1.7
-1.49
-0.33
-0.23
-1.02
0.29
-0.86
-3.78
0.26
EV-to-EBIT
-3.41
-36.23
-147
-87.72
-6.03
-27.78
-64.94
-29.07
-58.82
-67.11
-303
-435
-98.04
345
-116
-26.46
385
Earnings Yield (Joel Greenblatt) %
--
--
--
--
--
-743
-5792
-2083
-582
--
--
--
--
--
--
--
-- Forward Rate of Return (Yacktman) %

Valuation and Quality

Dec05
Dec06
Dec07
Dec08
Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
TTM Fiscal Period
79.56
34.61
23.47
20.13
177
11.73
16.24
34.34
21.24
23.37
6.31
12.65
22.83
7.34
21.12
94.52
33
Market Cap
75.29
24.67
13.73
18.87
169
14.91
11.19
30.11
19.27
14.41
2.79
2.16
13.82
-3.39
12.18
57.81
-5.64
Enterprise Value
611995
266218
180539
143819
770808
7925
880
1480
740
309
73.5
12.2
13.7
1.55
2.25
2.08
0.54
Month End Stock Price
31154
66346
-55662
-140664
-117639
-2699
240
145
-94.01
35.71
-24.34
9.32
4.73
2.42
0.79
1.17
0.61
Net Cash per Share
35269
81354
-45523
-139736
-117196
-2289
257
164
-81.81
39.35
-20.58
9.2
4.42
2.04
0.75
0.75
0.6
Net Current Asset Value
31154
66346
-55662
-140664
-117639
-2699
240
145
-94.01
35.71
-24.34
8.48
4.14
1.89
0.67
0.73
0.58
Net-Net Working Capital
--
--
--
--
--
-14198
-8680
-5829
-4690
-1424
-1223
-98.46
-70.21
-27.55
-15.07
-3.92
-2.6
Intrinsic Value: Projected FCF
--
--
--
--
-164109
-7798
-2567
-1709
-31.4
215
128
18.2
9.66
4.24
1.82
2.15
0.78
Earnings Power Value (EPV)
217
-1.72
-5.02
-60.62
-10.03
-5.21
1.37
6.47
-13.41
-6.9
-13.94
-4.76
-6.48
-10.08
--
--
-- Altman Z-Score
N/A
N/A
4
3
4
3
3
3
2
2
2
2
2
3
2
3
2
Piotroski F-Score
--
--
--
-25.91
-2.75
1.84
22.22
47.77
34.82
16.26
31.96
13.93
22.5
2.47
-3.41
-3.37
-3.2
Beneish M-Score
0.09
0.14
-1.31
-1.87
-24.33
0.37
0.92
0.56
-0.02
-0.33
-0.14
0.29
0.05
0
-0.07
-0.16
-0.03
Scaled Net Operating Assets
-8.14
-3.11
-58.8
-17.39
-130
-24.49
-26.05
-0.99
-51.04
6.1
36.55
14.19
-17.05
-9.74
-19.38
-1.87
-- Sloan Ratio %
22.13
9.05
1.57
0.21
0.52
1.41
11.54
7
0.61
1.56
0.73
7.47
4.95
8.6
4.11
16.26
13.07
Current Ratio
22.13
9.05
1.57
0.21
0.52
1.41
11.54
7
0.61
1.56
0.73
7.47
4.95
8.6
4.11
16.26
13.07
Quick Ratio
19.66
7.57
1.38
0.19
0.52
0.74
10.92
6.38
0.53
1.51
0.68
7.01
4.73
8.17
3.83
16.04
12.74
Cash Ratio
No Debt
No Debt
No Debt
No Debt
No Debt
--
--
--
--
--
--
N/A
N/A
No Debt
N/A
N/A
N/A Interest Coverage
1368k
685434
413097
241432
770808
899939
15300
4000
1580
840
355
76.15
26.6
13.7
2.85
3.17
2.98
Highest Stock Price
--
189718
131579
67320
104039
5814
740
860
600
199
68.5
10.5
11.2
1.29
1.06
1.03
0.53
Lowest Stock Price
--
--
--
-7.69
-64.29
-543
-1147
-25.75
-23.71
-164
-13.46
-1108
-60.7
-184
-98.35
-384
-128
Shares Buyback Ratio %
-8.27
-40.01
-58.17
-14.84
-5.04
-10.65
-62.61
-19.92
-23.42
-53.04
-52.32
-97.74
-21.49
-124
-42.73
-63.18
-- Buyback Yield %
--
--
--
--
-29.25
-100
--
--
--
--
--
--
--
--
--
--
-- YoY Rev. per Sh. Growth
--
-180
-248
30.85
27.89
99.38
13.89
25.81
16.09
54.59
59.9
69.56
50
51.12
64.82
58.7
64.66
YoY EPS Growth
--
--
-127
18.27
43.22
99.18
6.29
29.29
1.19
47.96
48.06
80.19
58.71
54.53
53.16
58.2
60.29
YoY EBITDA Growth
--
--
--
--
--
-6.55
67.53
78.85
75.91
63.53
34.66
40.41
56.36
62.66
63.15
60.31
60.7
5-Year EBITDA Growth Rate
--
--
--
--
--
0.01
0.01
0.02
0.03
0.05
0.08
0.44
1.4
2.96
7.68
19.81
59.87
Shares Outstanding (Basic Average)
0
0
0
0
0
0
0.02
0.02
0.03
0.08
0.09
1.04
1.67
4.73
9.39
45.44
61.1
Shares Outstanding (EOP)
--
--
--
1.39
1.62
0.79
0.24
-0.35
0.02
-0.5
0.83
0.8
1.61
0.82
1.49
1.66
1.64
Beta
03/30/09
03/30/10
04/14/11
03/09/12
03/28/13
03/19/14
03/24/15
03/11/16
03/15/17
03/21/18
02/26/19
03/09/20
03/02/21
  Filing Date
03/30/10
04/14/11
03/09/12
03/28/13
03/19/14
05/20/15
10/20/16
03/15/17
03/21/18
02/26/19
03/09/20
03/02/21
03/02/21
  Restated Filing Date
03/02/21
  Earnings Release Date
--
--
122
101
--
234
360
358
391
381
359
336
325
220
258
--
-- Number of Shareholders
6
7
10
8
8
12
18
24
--
--
19
15
15
7
8
11
11
Number of Employees
* All financial numbers are in millions except for per share data, ratios and percentage change.
GuruFocus Manual of Stocks™  |  Jan 23, 2022
Cellectar Biosciences Inc (NAS:CLRB)
www.gurufocus.com/stock/NAS:CLRB

Explanation

1. Predictability Rank

GuruFocus Predictability Rank is a proprietary ranking of the consistency of a business. We rank the predictability of companies based on the consistency of their revenue per share and EBITDA (earnings before interest, tax, depreciation and amortization) per share over the past 10 fiscal years. Our study found that there is a strong correlation between the stock performance and the predictability of a business. Over the long term, companies with higher predictability also have better stock performance.

The rank is from 1-star to 5-star, with 5-star as the best.

2. Financial Strength

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

  1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
  2. Debt to revenue ratio. The lower, the better.
  3. Altman Z-Score.

The rank is from 1 to 10, with 10 as the highest.

A Financial Strength rank of 8 or above indicates good financial strength; between 4-7 indicates fair financial strength; 3 or below means poor financial strength.

3. Profitability Rank

GuruFocus Profitability Rank indicates how profitable a company is and how likely it is that the company's business will stay that way. It is based on these factors:

  1. Operating Margin %.
  2. Piotroski F-Score.
  3. Trend of the Operating Margin percentage (five-year average). A company with an uptrend in profit margin will have a higher rank.
  4. Consistency of the profitability.
  5. Predictability Rank.

The rank is from 1 to 10, with 10 as the highest.

A Profitability Rank of 8 or above indicates good profitability; between 4-7 indicates fair profitability; 3 or below means poor profitability.

4. Peter Lynch Chart

In Peter Lynch's excellent book, "One Up on Wall Street," he used many charts to illustrate the valuation of stocks. “A quick way to tell if a stock is overpriced is to compare the price line to the earnings line. If you bought familiar growth companies – such as Shoney’s, The Limited, or Marriott – when the stock price fell well below the earnings line, and sold them when the stock price rose dramatically above it, the chances are you’d do pretty well.”

The original Peter Lynch Chart does have limitations due to the right side price scale is pre-set at 15 times the earnings scale on the left side. When the stock price and earnings line coincide, the price-to-earnings ratio is always 15 times. Instead of using the fixed PE Ratio of 15, our approach is using 15-year historical median PE without NRI Ratio for each stock.

The Peter Lynch Chart with earnings line at median PE without NRI ratio works well for the companies with steady growth and earnings trends, or the stalwarts, as coined by Lynch. These companies tend to be found in sectors such as consumer staples, healthcare, and utilities, where the consumption of the product or service is relatively independent of economic conditions. It does not work well with the sectors that are cyclical: industrials, chemicals, durable goods, and so forth.

5. GF Value

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

  1. Possible Value Trap, Think Twice
  2. Significantly Overvalued
  3. Modestly Overvalued
  4. Fairly Valued
  5. Modestly Undervalued
  6. Significantly Undervalued
There is only a sufficient margin of safety when the stock is undervalued.

Disclaimer

GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.